Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared a post on X:
“Excellent overview of treatment for early stage HER2 positive disease by Mothaffar Rimawi – we need biomarkers to tailor therapy for this population.”
